ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications wor…
$172.11+2.66%
报价 2026-11-06
市值
$4.3B
EV
$5.26B
PE (TTM)
90.1x
预期 PE (FY2026)
19.7x
52 周区间距高点 -8.1%
$115.45$187.26
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 8.69 → 9.67（1.1x） | 17.8 |
| FY+32028-12 | 1.1x | 8.69 → 10.40（1.2x） | 16.6 |
毛利率 36% · TTM 收入 $2183M · 基数 EPS 8.69（调整后）
电话会信号
辅助标签Q3 20262026-11-05
扩产
指引 维持
信心 4
分析师 4
“We expect our consumables and systems businesses to be reliable growers with an industry acceptable profit margin.”
原文引用（1）
- 扩产：we invested $12 million of cash spend for quality system and product-related remediation activities, $6 million on restructuring and integration and $16 million on CapEx for general maintenance and capacity expansion
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ICUIICU Medical, Inc. | $4.3B | +2.7% | -0.8% | 36.4% | 90.1x | 20.0x | 52.4x | |
| HAEHaemonetics Corporation | $5.46B | -3.4% | +7.0% | 59.8% | 58.9x | 24.8x | 18.9x | |
| LIVNLivaNova PLC | $4.96B | -1.3% | +10.4% | 67.4% | 25.1x | 22.4x | 38.4x | GARP |
| TVTXTravere Therapeutics, Inc. | $4.76B | +1.5% | +40.1% | 94.4% | – | 4103.2x | 705.8x | |
| HTFLHeartflow, Inc. Common Stock | $4.56B | +0.9% | +43.4% | 83% | – | – | – | 高增长 |
| TARSTarsus Pharmaceuticals, Inc. | $3.38B | +1.6% | +56.4% | 90.6% | – | – | 63.5x | |
| ARQTArcutis Biotherapeutics, Inc. | $3.21B | -5.4% | +37.9% | 91.1% | 144.4x | 94.1x | 102.4x | |
| IRONDisc Medicine, Inc. | $3.03B | +0.6% | -47.5% | 0% | – | – | – | |
| PRGOPerrigo Company plc | $2.2B | +0.9% | -6.0% | 30.7% | – | – | 12.9x | |
| 同行中位数 | – | – | +24.2% | 75.2% | 58.9x | 59.5x | 50.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。